Osteoarthritis year in review 2023: metabolite and protein biomarkers

To highlight the advances over the past year in metabolite/protein biomarkers for osteoarthritis (OA).A literature search of five databases including PubMed, Web of Science, Scopus, Ovid Medline, and Embase was performed for studies on metabolite/protein/peptide/biochemical markers for OA published between April 1st, 2022 and March 31st, 2023. Records were then screened to include only original research articles using directly collected human specimens, in English language, and with full text available. Data from eligible studies were systematically extracted and summarized.A total of 1600 unique records were extracted, out of which 46 fulfilled the inclusion criteria and were used for data extraction. Forty-one of these 46 studies focused on biomarkers for OA/OA severity/progression, four on OA clustering, and one on OA treatment outcomes. Twenty-nine studied protein markers for OA, thirteen studied metabolite markers, and four studied both. While many studies were the validation of the previously reported biomarkers, a number of novel metabolite/protein biomarkers and biomarker panels were reported in the past year. Biomarker panels might be useful to subset OA patients.The number of studies on OA clustering is rising. Although validation in larger cohorts is needed in order to utilize reported biomarkers in clinical practice, these discoveries help better understand the pathogenesis of OA, provide insights into possible mechanisms underlying poor treatment outcomes, and aid in developing personalized treatment based on OA subtypes.